CNCure Co., Ltd.
June 23, 2026
Theater 3
Type: Company Presentation
Focus Area:
Oncology
CNCure Co., Ltd. is a South Korea–based biotechnology company developing bacteria‑based cancer immunotherapies and radiotheranostic platforms for precision oncology.
Its lead candidate, CNC‑101, is a genetically attenuated Salmonella typhimurium strain engineered to reprogram the tumor microenvironment and boost anti‑tumor immunity. CNC‑105 utilizes controlled bacterial gene expression to deliver therapeutic payloads safely and effectively.
The company also advances molecular imaging and radio‑theranostic agents, such as ¹⁸F‑labeled tracers for simultaneous diagnosis and treatment. Key programs include CNC‑201 for melanoma detection and CNC‑301 for targeted radiopharmaceutical therapy.
Founded in 2019 and based at the Chonnam National University Biomedical Research Center in Hwasun, Jeonnam, CNCure is privately held and a portfolio company of JLABS Korea, supported by national R&D initiatives accelerating next‑generation microbial oncology innovation.
Company HQ City:
Hwasun-gun
Company HQ State:
Jeollanam-do
Company HQ Country:
Korea, Republic of
Year Founded:
2019
Lead Product in Development:
CNC-101, bacteria based cancer immunotherapy
CEO
Jung-Joon Min and Joong Gon Park
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
3 (CNC-101 immunotherapy, CNC-105 drug delivery system, CNC-301 radiopharmaceutical therapy)
When you expect your next catalyst update?
3Q 2027
What is your next catalyst (value inflection) update?
Completion of IND-enabling studies for CNC-101 and IND submission
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}